Drug Trial Radar · NCT04046484
PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients
Last checked: Nov 19, 2026Latest source record: May 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jan 19, 2018
Primary completion
Apr 12, 2019
Study completion Jun 30, 2019
Sponsor
- Lead sponsor
- Pharmazz, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a prospective, multicentric, randomized, double blind, parallel, saline controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide) therapy along with standard supportive care in patients of acute ischemic stroke.
Conditions
- Acute Stroke
- Cerebral Ischemia
Interventions
Normal Saline along with standard treatmentDrug
The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
PMZ-1620 along with standard treatmentDrug
PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of PMZ-1620 related adverse eventsTime frame: 90 days
- Number of patients not receiving full treatmentTime frame: 90 days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Paras Hospital
Gūrgaon, India
Nizam's Institute of Medical Sciences
Hyderabad, India
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Lucknow, India
Dayanand Medical College & Hospital
Ludhiana, India
Department of Neurology, Christian Medical College and Hospital
Ludhiana, India
New Era Hospital & Research Institute
Nagpur, India
All India Institute of Medical Sciences
New Delhi, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.